A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...

The most recent trading session ended with Eli Lilly (LLY) standing at $909.32, reflecting a -1.65% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 0.4%.

Shares of Eli Lilly & Co. LLY slid 1.65% to $909.32 Thursday, on what proved to be an all-around favorable trading session ...

A woman from Chester Springs, Pennsylvania, is one of the first patients in the country to receive a new FDA-approved ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...

A study from tirzepatide's manufacturer found that the GLP-1 drug could significantly improve heart failure symptoms.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 600.18% and ...

Delve into the world of radiopharmaceuticals: explore their mechanisms, promising candidates, and the key players driving ...

A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

The healthcare company's pivot into a new set of technologies will have many implications for the stock.